Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial - The Lancet
Chemotherapy protocol definition form | Download Scientific Diagram
PDF) Dose Dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel (Dose Dense AC Followed by T) Regimen for Breast Cancer
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial - The Lancet
Optimising dose-dense regimens for early breast cancer | Cancer World Archive
Chemotherapy protocol a for HR ALL patients | Download Table
Effect of Number of Treatment Cycles of Adjuvant Chemotherapy on Clinical Outcomes | Research To Practice
Breast Cancer Update .com - Web Guide 1 2003
Anthracycline-free or short-term regimen as adjuvant chemotherapy for operable breast cancer: A phase III randomized non-inferiority trial - The Lancet Regional Health – Western Pacific
Chemotherapy regimens for breast cancer. | Download Table
Protocol MCP841 chemotherapy regimen. | Download Table
Chemotherapy Administration Sequencing: An Update on the Current Literature
Chemotherapy-Induced Nausea and Vomiting: From Guideline to Clinical Practice - Pharmacy Connection
Dose Dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel... | Download Table
Pregnancy-Associated Breast Cancer
National Surgical Adjuvant Breast and Bowel Project (NSABP)
Dose-dense chemotherapy for breast cancer: what does the future hold? | Future Oncology
JCM | Free Full-Text | Current Treatment Landscape for Early Triple-Negative Breast Cancer (TNBC)
Pegylated liposomal doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant chemotherapy in locally advanced breast cancer (registration number: ChiCTR1900023052) | Scientific Reports
Recommended antiemetic regimens for HEC and AC-containing regimens... | Download Table
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial - The Lancet Oncology
1607-Breast adjuvant AC (DOXOrubicin and CYCLOPHOSPHamide) dose dense followed by PACLitaxel dose de | eviQ
